Kenvue Inc. (KVUE)
| Market Cap | 46.25B |
| Revenue (ttm) | 15.30B |
| Net Income (ttm) | 1.06B |
| Shares Out | 1.92B |
| EPS (ttm) | 0.55 |
| PE Ratio | 44.31 |
| Forward PE | 21.01 |
| Dividend | $0.82 (3.41%) |
| Ex-Dividend Date | May 14, 2025 |
| Volume | 4,047,479 |
| Open | 24.26 |
| Previous Close | 24.44 |
| Day's Range | 24.06 - 24.61 |
| 52-Week Range | 17.67 - 25.17 |
| Beta | 0.97 |
| Analysts | Buy |
| Price Target | 25.25 (+4.82%) |
| Earnings Date | May 8, 2025 |
About KVUE
Kenvue Inc. operates as a consumer health company in the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. Its Skin Health and Beauty segment provides face and body care, hair, sun, and other... [Read more]
Financial Performance
In 2024, Kenvue's revenue was $15.46 billion, an increase of 0.07% compared to the previous year's $15.44 billion. Earnings were $1.03 billion, a decrease of -38.10%.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for KVUE stock is "Buy." The 12-month stock price forecast is $25.25, which is an increase of 4.82% from the latest price.
News
Kenvue: First Quarter A Sign Of Challenging Times, But Still A Solid Long-Term Play
Kenvue, a solid dividend-paying stock spun off from Johnson & Johnson, offers long-term upside despite current economic challenges and declining consumer sentiment. Recent earnings showed slight reven...
Kenvue, Inc. (KVUE) Q1 2025 Earnings Call Transcript
Kenvue, Inc. (NYSE:KVUE) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Sofya Tsinis - Head of Investor Relations Thibaut Mongon - Chief Executive Officer and Director P...
Kenvue Boosts 2025 Sales Growth View
The Johnson & Johnson spinoff that makes Tylenol and Benadryl, logged earnings growth ahead of expectations, named a new chief financial officer and boosted its sales-growth projection for the year, w...
Listerine, Tylenol Maker Kenvue Tops Estimates, Lifts Sales Outlook
Shares of Kenvue (KVUE) rose in premarket trading Thursday after the maker of Band-Aid, Tylenol, and Listerine reported first-quarter results better than analysts' estimates.
Kenvue first-quarter results beat estimates on strength in self care unit
Kenvue beat analysts' expectations for first-quarter profit and revenue on Thursday, as strong demand for its self-care products including cough and cold medicines Tylenol and Benadryl helped offset a...
Kenvue Reports First Quarter 2025 Results
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced financial results for the first quarter ended March 30, 2025. “In Q1, our teams executed our plans while continuing to navigate ...
Kenvue Announces Chief Financial Officer Transition
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE), today announced the appointment of Amit Banati as the Company's Chief Financial Officer, effective May 12, 2025. He will be responsible for ove...
Buy 3 "Safer" Dividend Kings Of 25 From May's 55
The May collection of Dividend Kings grew to 55, with Automatic Data Processing and RLI Corporation joining, despite two companies dropping off for not increasing dividends. Six top-yield Dividend Kin...
Best Dividend Aristocrats For May 2025
Despite a strong start, the Dividend Aristocrats are underperforming the S&P 500 in April, with NOBL down 4.88% and SPY down 1.53%. The best-performing Dividend Aristocrats YTD include Consolidated Ed...
Loeb's Third Point builds stake in Band-Aid maker Kenvue
Billionaire investor Daniel Loeb's hedge fund Third Point is building a stake in Kenvue , sources familiar with the matter said on Friday, as some investors are pushing for strategic changes at the co...
Kenvue to Announce First Quarter 2025 Results on May 8, 2025
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will announce its first quarter 2025 financial results before market open on May 8, 2025. The company will host a conference call and webcast at...
Two Stocks To Consider During Market Unrest To Provide Income Stability
Investors should remain calm amid market volatility and consider buying during price dips, with 2025 expected to see more turbulence. Kenvue's strong brand portfolio and solid liquidity offer price st...
Kenvue Declares Quarterly Cash Dividend
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors has declared a quarterly dividend of $0.205 per share on its common stock. This quarterly dividend i...
Kenvue Announces 5-Year Collaboration with Microsoft to Transform Digital Operations
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue announced a five-year collaboration with Microsoft to transform digital operations through Artificial Intelligence (AI) technologies.
OGX® Haircare Introduces Shay Mitchell as First Global Brand Ambassador
New campaign introduces new Bond Protein Repair hair line designed to deliver effective bonding repair – at a fraction of the price of prestige brands SUMMIT, N.J. , April 7, 2025 /PRNewswire/ -- Ken...
Best Dividend Aristocrats For April 2025
Dividend Aristocrats are outperforming the S&P 500 in 2025, demonstrating resilience, with NOBL up 1.78% YTD versus SPY's 4.9% decline. Top performers include Consolidated Edison (+22.98%), Brown & Br...
Neutrogena® and John Cena Team Up for the Ultimate Disappearing Act in New Ultra Sheer ® Mineral Sunscreen Campaign
The Brand's Latest Mineral Sunscreen AddressesTop Consumer Barriers to Daily Sunscreen Use SUMMIT, N.J. , March 31, 2025 /PRNewswire/ -- Kenvue Inc. (NYSE: KVUE) continues to push the boundaries of su...
Buy 3 'Safer' Dividend Kings Of 25 From March's 55
The article highlights 55 Dividend Kings, noting that five of the top ten by yield offer annual dividends from a $1K investment exceeding their single share prices. Analysts predict top-ten Kingly net...
2025 Dividend Kings: Strong Run Continues
The Dividend Kings are outperforming the S&P 500 in 2025 by 4.57%. Top performers include National Fuel & Gas (+30.21%), Consolidated Edison (+22.66%), and AbbVie (+20.40%). Promising Dividend Kings i...
Kenvue Ribbon-Cutting Marks Official Opening of New Global Headquarters in Summit, New Jersey
SUMMIT, N.J.--(BUSINESS WIRE)--Today, Kenvue Inc. (NYSE: KVUE) held a ribbon-cutting ceremony for its new 290,000 sq. ft. global headquarters in Summit, New Jersey.
Kenvue + Johnson & Johnson: I Choose To Own The Whole 'Humpty Dumpty'
Johnson & Johnson's spin-off of Kenvue has created two resilient defensive stocks in the healthcare sector, ideal for accumulation during market volatility. Despite being off their highs, both JNJ and...
Buy 2 March S&P 500 Dividend Aristocrats Out Of 37 'Safer'
Four of the ten lowest-priced Dividend Aristocrats, including Franklin Resources and Realty Income, are ready to buy with annual dividends exceeding their single share prices. Analysts forecast 15.93%...
Kenvue to Showcase New Clinical Data on Skin Longevity, Hydration and Sun Protection at American Academy of Dermatology Association Meeting
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will share new clinical data demonstrating how its iconic brands are leveraging the latest science to shape the future of the Skin Health & Be...
Faber Report: Kenvue settles proxy fight with activist Starboard
CNBC's David Faber breaks down the latest news on Kenvue.
Kenvue settles proxy fight with activist Starboard, appoints three directors
Consumer health company Kenvue said on Wednesday it had appointed three new directors to its board as part of an agreement with activist investor Starboard Value.